Clinical trials · Boston, MA
Metastatic Prostate Cancer clinical trials in Boston
We’re tracking 73 recruiting metastatic prostate cancer studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT06496256Recruiting
Barrigel gel for radiation after prostate removal
This trial tests a gel placed in the rectum during radiation therapy to protect healthy tissue after prostate removal. It is for men whose prostate cancer has come back (PSA rise) and who need radiation to the prostate bed.
Boston, MassachusettsAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Boston, MassachusettsAges 18–90 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Boston, MassachusettsAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Boston, MassachusettsAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Boston, MassachusettsAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Boston, MassachusettsAges 18–100 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Boston, MassachusettsAges 18 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Boston, MassachusettsAges 18 years+ - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Boston, MassachusettsAges 18–130 - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Boston, MassachusettsAges 18 years+ - NCT05753722RecruitingPhase 1
First trial for PRTH-101 alone or with pembrolizumab
This early study tests PRTH-101, given by itself or with pembrolizumab, in people with advanced cancers that have spread or cannot be removed by surgery. The goal is to see if it is safe and how it affects the cancer.
Boston, MassachusettsAges 18 years+ - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06800313RecruitingPhase 1/Phase 2
A study of HLD-0915 for metastatic prostate cancer
This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.
Boston, MassachusettsAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Boston, MassachusettsAges 12 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Boston, MassachusettsAges 18–100 - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Boston, MassachusettsAges 18–100 - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Boston, MassachusettsAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Boston, MassachusettsAges 18 years+
Hear when a new Metastatic Prostate Cancer trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Metastatic Prostate Cancer trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting metastatic prostate cancer studies listed above.
- Dana-Farber Cancer Institute · 16 studies
- Massachusetts General Hospital · 6 studies
- Beth Israel Deaconess Medical Center · 4 studies
- Brigham and Women's Hospital
- Dana Farber Mass General Brigham Cancer Care Inc
- Dana-Farber Cancer Institute - Merrimack Valley
- Dana-Farber Cancer Institute at Foxborough
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
What taking part in a metastatic prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic prostate cancer studies in Massachusetts.
Common questions
- Are there metastatic prostate cancer clinical trials near Boston?
- Yes. We're currently tracking 73 recruiting metastatic prostate cancer studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate cancer study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate cancer studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.